Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 8,81 € (+1.298,41 %). Medianen er 9,11 € (+1.346,03 %).
| Køb |
18 |
| Behold |
1 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Aldeyra adds Darlene Deptula-Hicks to board of directors
Aldeyra has appointed Darlene Deptula-Hicks to its board of directors; she brings more than 30 years of experience in the biotech sector and expertise as a finance executive at public and private life-science companies. Deptula-Hicks is currently interim CFO of Normunity and was previously CFO of F-star Therapeutics; her experience with IPOs, capital raising and M&A is expected to support potential commercialization of Aldeyra’s therapies. Aldeyra is developing RASP modulators and is advancing reproxalap and ADX-2191 in late-stage development; the company has a market capitalization of $104 million, a current ratio of 2.72, and its stock has traded well below last year’s level since the start of the year, while analyst price targets remain between $2 and $13. » Mere på de.investing.com
Aldeyra Therapeutics repays $15 million loan and terminates credit facility
Aldeyra Therapeutics repaid all outstanding liabilities of $15 million on April 1, thereby terminating the loan agreement with Hercules Capital in accordance with the contract. The company reports a balance sheet with more cash than debt and expects that cash, cash equivalents and marketable securities will fund operations through 2028. At the same time, Aldeyra faces regulatory pressure following an FDA Complete Response Letter for Reproxalap; analyst reactions are mixed (BTIG: buy, price target $9.00; H.C. Wainwright: neutral, price target $2.00). The stock trades well below last year’s level, reflecting the ongoing uncertainties. » Mere på de.investing.com
Aldeyra Therapeutics: chief development officer Dr. Stephen G. Machatha to resign by March 2026
Aldeyra Therapeutics announced that Dr. Stephen G. Machatha has voluntarily resigned as chief development officer; his last day will be no later than March 31, 2026. The company and Machatha reached a transition agreement under which he will remain employed through his departure, continue to receive his base salary and benefits, and have outstanding equity awards remain unchanged. As part of the agreement, Machatha will receive a one‑time payment of $88,000 and may receive an additional $88,000 if he signs further release agreements after leaving. The company emphasized that the resignation is not the result of any disagreement with management or the board. » Mere på de.investing.com
Aldeyra receives EMA orphan drug status for ADX-2191 to treat rare retinal diseases
Aldeyra Therapeutics has been granted orphan drug status by the European Medicines Agency for ADX-2191 for the treatment of inherited retinal dystrophies, including retinitis pigmentosa. The company will benefit from regulatory advantages and plans to conduct further clinical trials, while its financial position is described as solid. Additionally, progress has been reported in the development and approval applications of other medications. » Mere på de.investing.com
Aldeyra receives positive FDA feedback for eye drug Reproxalap
Aldeyra Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted the resubmitted approval application for its eye drug Reproxalap, intended for the treatment of dry eye disease. The FDA's decision is expected by December 16, 2025, following the submission of additional clinical data. Analysts remain optimistic about the stock, and the company is financially well positioned to continue its development programs. » Mere på de.investing.com
Virksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 0 | - |
| Bruttofortjeneste | 0 | - |
| Nettoresultat | -3,32 mio. | 49,29 % |
| EBITDA | -3,19 mio. | 47,71 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 38,23 mio. € |
Antal aktier | 60,36 mio. |
Højeste/laveste i 52 uger | 5,40 € - 0,48 € |
| Udbytte | Nej |
Beta | 1,29 |
P/E (PE Ratio) | -2,18 |
PEG (PEG Ratio) | -0,02 |
K/I (PB Ratio) | 0,00 |
P/S (PS Ratio) | 0,00 |
Virksomhedsprofil
Aldeyra Therapeutics, Inc., et biotekselskab, udvikler og kommercialiserer lægemidler til immunmedierede øjen- og systemiske sygdomme. Selskabets førende produktkandidat er reproxalap, en modulator af reaktive aldehydarter (RASP), som er i fase III-forsøg til behandling af tørre øjensygdomme og allergisk konjunktivitis. Selskabet udvikler også ADX-629, en første-i-klassen oralt administreret RASP-modulator, som er i fase II-forsøg til psoriasis, astma og COVID-19; og ADX-2191, en dihydrofolatreduktasehæmmer, som er i fase III til forebyggelse af proliferativ vitreoretinopati og i fase II-forsøg til behandling af retinitis pigmentosa samt til behandling af primært vitreoretinalt lymfom. Selskabet har en licensaftale med Madrigal Pharmaceuticals, Inc. om udvikling af ADX-1612, som hæmmer proteinchaperonen til behandling af inflammatoriske sygdomme. Selskabet var tidligere kendt som Aldexa Therapeutics, Inc. og ændrede navn til Aldeyra Therapeutics, Inc. i marts 2014. Aldeyra Therapeutics, Inc. blev stiftet i 2004 og har hovedkontor i Lexington, Massachusetts.
| Navn | Aldeyra Therapeutics |
| CEO | Todd C. Brady |
| Hjemsted | Lexington,
ma USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Bioteknologi |
| Børsnotering | 02.05.2014 |
| Medarbejdere | 6 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | ALDX |
Frankfurt | 137.F |
Düsseldorf | 137.DU |
München | 137.MU |